Table 2.
Descriptive statistics of substance use parameters, health services contacts, and liver enzyme activity
| Patients with masculine depression (Ntotal = 81) |
Patients with non-masculine depression (Ntotal = 82) |
Healthy control subjects (Ntotal = 176) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| N | M/F | SD | N | M/F | SD | N | M/F | SD | |
| Alcohol | |||||||||
| AUDIT score | 80 | 9.8 | 9.2 | 80 | 2.9 | 3.1 | 176 | 4.4 | 3.1 |
| % AUDIT score (≥ 8) | 80 | 44 | 80 | 5 | 176 | 15 | |||
| % AUDIT score (≥ 20) | 80 | 20 | 80 | 1 | 176 | 0 | |||
| % Binge drinking Yes vs. No (2-week) | 63 | 35 | 70 | 4 | 167 | 31 | |||
| Binge drinking frequency (2-week; drinks per week) | 63 | 1.1 | 2.9 | 70 | 0.0 | 0.1 | 167 | 0.3 | 0.5 |
| Binge drinking severity (2-week; drinks per week) | 63 | 0.5 | 0.9 | 70 | 0.0 | 0.2 | 167 | 0.3 | 0.6 |
| % Binge drinking Yes vs. No (24-month) | 60 | 62 | 70 | 27 | 165 | 50 | |||
| Binge drinking frequency (24-month; drinks per week) | 60 | 0.5 | 1.0 | 70 | 0.0 | 0.1 | 165 | 0.1 | 0.3 |
| Binge drinking severity (24-month; drinks per week) | 60 | 1.1 | 1.1 | 70 | 0.3 | 0.6 | 165 | 0.7 | 0.9 |
| Nicotine | |||||||||
| % Cigarette smoking (yes) | 81 | 47 | 81 | 30 | 175 | 6 | |||
| FTND score | 81 | 2.0 | 2.7 | 81 | 1.0 | 2.0 | 175 | 0.1 | 0.4 |
| Drugs | |||||||||
| % Use of sedative medication (4-week) | 72 | 28 | 77 | 31 | 174 | 5 | |||
| % Use of cannabis (4-week) | 74 | 26 | 77 | 5 | 174 | 3 | |||
| % Use of stimulants (4-week) | 75 | 3 | 76 | 1 | 174 | 1 | |||
| % Use of opioids (4-week) | 75 | 3 | 76 | 3 | 174 | 1 | |||
| % Use of cocaine (4-week; yes) | 75 | 0 | 76 | 0 | 173 | 0 | |||
| % Use of hallucinogens/PCP (4-week) | 75 | 3 | 76 | 0 | 173 | 0 | |||
| % Use of sedative medication (lifetime) | 76 | 41 | 81 | 36 | 174 | 11 | |||
| % Use of cannabis (lifetime) | 77 | 53 | 80 | 18 | 174 | 18 | |||
| % Use of stimulants (lifetime) | 76 | 20 | 79 | 6 | 174 | 3 | |||
| % Use of opioids (lifetime) | 78 | 12 | 79 | 3 | 176 | 1 | |||
| % Use of cocaine (lifetime) | 78 | 9 | 79 | 1 | 175 | 2 | |||
| % Use of hallucinogens / PCP (lifetime) | 78 | 17 | 79 | 3 | 174 | 2 | |||
| Number of health services contacts | |||||||||
| Due to physical complaints (6-month) | 80 | 3.5 | 3.6 | 80 | 2.9 | 4.2 | 175 | 1.0 | 1.6 |
| Due to mental complaints (12-month) | 80 | 11.0 | 15.4 | 80 | 12.0 | 14.8 | 175 | 0.1 | 0.5 |
| GGT activity (U/L) | 81 | 33.1 | 30.1 | 82 | 28.3 | 21.8 | 176 | 25.8 | 38.7 |
The table shows the valid number of subjects analyzed (N), means (M) or relative frequencies (F) and standard deviation (SD). AUDIT Alcohol Use Disorder Identification Test, FTND Fagerström Test for Nicotine Dependence, GGT gamma-glutamyl transferase, 2-week previous 2 weeks, 4-week previous 4 weeks, 6-month previous 6 months, 12-month previous 12 months, 24-month previous 24-months